期刊文献+

孝感地区高脂血症人群ApoE/SLCO1B1基因多态性与血脂水平及他汀类药物相关性研究

Correlation of ApoE/SLCO1B1 gene polymorphisms with lipid levels and statins in hyperlipidemic population in Xiaogan area
下载PDF
导出
摘要 目的探讨孝感地区高血脂人群ApoE和SLCO1B1基因位点多态性分布,从分子水平研究该基因不同位点与血脂水平的相关性,评估他汀类药物个体化用药的疗效,为临床高血脂个体化防治提供理论依据。方法选择2022年7月至2023年7月孝感市中心医院900例患者作为研究对象,测定所有患者的血脂指标,包括甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、极低密度脂蛋白胆固醇(VLDL-C),采用实时荧光定量PCR法定性检测患者外周血全血样本中ApoE基因的ApoE2(526C>T)和ApoE4(388T>C)位点的基因多态性和SLCO1B1基因的SLCO1B1^(*)1b(388A>G)和SLCO1B1^(*)5(521T>C)位点的基因多态性,与国内已报道的其他地区高血脂人群的数据进行比较,分析不同地区间的基因型分布差异。结果血脂异常人群ApoE基因型分布频率为E2/E2(0.34%),E2/E3(14.00%),E3/E3(68.89%),E3/E4(13.22%),E2/E4(1.78%)和E4/E4(1.78%)。SLCO1B1基因型频率:^(*)1a/^(*)1a(7.22%),^(*)1a/^(*)1b(32.89%),^(*)1b/^(*)1b(39.22%),^(*)1a/^(*)5(0.11%),^(*)1a/^(*)15(6.22%),^(*)1b/^(*)15(13.00%),^(*)15/^(*)15(1.33%)。结论孝感地区ApoE中E3/E3基因型所占人数最多,SLCO1B1基因中^(*)1b/^(*)1b型占比最高,即孝感地区高脂血症人群中使用他汀类药物后,大部分人疗效较好,肌病风险较低。ApoE基因型E4基因频率分布与血脂水平差异有统计学意义(P<0.05)。ApoE/SLCO1B1其他位点与血脂水平差异均无统计学意义(P>0.05)。 【Objective】To investigate the polymorphism distribution of ApoE and SLCO1B1 gene loci in hyperlipidemia population in Xiaogan area,study the correlation between different loci of the gene and lipid level from the molecular level,evaluate the efficacy of personalized statin drug administration,and provide theoretical basis for the individualized prevention and treatment of hyperlipidemia.【Methods】Nine hundred patients in Xiaogan Central Hospital from July 2022 to July 2023 were selected as the study objects,and the blood lipid indexes of all patients were determined,including triglyceride(TG),total cholesterol(TC),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),and very low density lipoprotein cholesterol(VLDL-C).The polymorphism of ApoE2(526C>T)and ApoE4(388T>C)locus of ApoE gene and SLCO1B1^(*)1b(388A>G)and SLCO1B1^(*)5(521T>C)locus of SLCO1B1 gene were qualitatively detected by real-time fluorescence quantitative PCR method,which were compared with the reported data of hyperlipidemics from other regions in China,and the differences in genotype distribution among different regions were analyzed.【Results】The distribution frequency of ApoE genotype in dyslipidemia population was E2/E2(0.34%),E2/E3(14.00%),E3/E3(68.89%),E3/E4(13.22%),E2/E4(1.78%)and E4/E4(1.78%).SLCO1B1 genotype frequency:^(*)1a/^(*)1a(7.22%),^(*)1a/^(*)1b(32.89%),^(*)1b/^(*)1b(39.22%),^(*)1a/^(*)5(0.11%),^(*)1a/^(*)15(6.22%),^(*)1b/^(*)15(13.00%),^(*)15/^(*)15(1.33%).【Conclusion】E3/E3 genotype accounted for the largest proportion of ApoE in Xiaogan area,and^(*)1b/^(*)1b genotype in SLCO1B1 gene accounted for the highest proportion,that is,after the use of statins in hyperlipidemia population in Xiaogan area,most of them had a good effect and a low risk of myopathy.The E4 gene frequency distribution of ApoE genotype had statistical significance with blood lipid level(P<0.05).There was no significant difference between ApoE/SLCO1B1 and lipid levels(P>0.05).
作者 宁洋 付汉东 NING Yang;FU Handong(Postgraduate Training Base of Jinzhou Medical University(Xiaogan Central Hospital),Xiaogan,Hubei 432000,China;Xiaogan Hospital Affiliated to Wuhan University of Science and Technology(Xiaogan Central Hospital),Xiaogan,Hubei 432000,China)
出处 《中国医学工程》 2024年第12期24-28,共5页 China Medical Engineering
关键词 血脂水平 APOE SLCO1B1 他汀类药物 基因多态性 lipid level ApoE SLCO1B1 statins gene polymorphism
  • 相关文献

参考文献18

二级参考文献127

  • 1李师承,施莹,石磊,曾涛,薛炎,林小靖,刘瑜,吉庆伟,刘伶,林英忠.阿托伐他汀药物基因多态性对冠心病调脂治疗的影响[J].临床心血管病杂志,2020,36(2):124-128. 被引量:7
  • 2张莉莉,吕安林,贾国良,王海昌.载脂蛋白E基因多态性对他汀类药物调脂消斑的影响[J].第四军医大学学报,2004,25(11):1029-1031. 被引量:10
  • 3中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5233
  • 4Stone N J,Robinson J,Lichtenstein AH. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coil Cardiol,2013,(13):06028-06022.
  • 5Kolata G. Experts reshape treatment guide for cholesterol[N].New York Tim es,2013.
  • 6Smith SC,Benjamin E J,Bonow RO. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease:2011 update:a guideline from the American Heart Association and American College of Cardiology Foundation.Circulation[J].{H}Journal of the America College of Cardiology,2011,(22):2458-2473.
  • 7卫生部心血管病防治研究中心.中国心血管病报告2012[M]{H}北京:中国大百科全书出版社,20132-4.
  • 8Shang Q,Liu Z,Chen K. A systematic review of Xuezhikang,an extract from red yeast rice,for coronary heart disease complicated by dyslipidemia[J].{H}Evidence-based Complementary and Alternative Medicine,2012.636547.
  • 9Feng Y,Xu H,Chen K. Natural polypill Xuezhikang:its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions[J].{H}JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE,2012,(4):318-328.
  • 10Keskitalo JE, Pasanen MK, Neuvonen PJ, et al. Different effects of the ABCG2 c. 421C > A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin [J].Pharmacogenomics, 2009, 10(10): 1617-1624.

共引文献207

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部